Our Research and Development Facilities
Bristol-Myers Squibb's drug discovery and development work takes place across a network of state-of the-art facilities worldwide. For information about a specific Bristol-Myers Squibb facility, click the link from the list below or view the complete list of our worldwide facilities.
The Biocon Bristol-Myers Squibb Research & Development Center (BBRC) is a collaboration between Bristol-Myers Squibb and Syngene International, a Biocon- group company, and is based in Bangalore, India. Fully operational since 2009, the site is involved in Target Identification, Lead Discovery and Lead Optimization all the way through to early stage Pharmaceutical Development and Clinical Biomarkers R&D.
Bristol-Myers Squibb's European Research & Development operations have been based here since 2003. Employees work in eight buildings located in an office park set in the countryside.
In Cambridge, Bristol-Myers Squibb scientists will focus on the company’s ongoing discovery efforts, molecular discovery technologies and discovery platform chemistry in state-of-the-art lab space. The new research site is expected to open in 2018.
Hopewell, New Jersey
Acquired in 1997, some of the company's most important drug discovery work takes place at this 433-acre site. Eight major buildings reside on the site, totaling 800,000 square feet.
The 11.2 acre research facility is located on the Wirral Peninsula between Chester and Liverpool. Scientists here investigate new medicinal compounds and how they can be manufactured efficiently on a commercial scale.
New Brunswick, New Jersey
Purchased in 1905 when E.R. Squibb & Sons relocated operations from Brooklyn, New York, this campus has 40 buildings that total 1.9 million square feet on 96 acres. The site has evolved from a manufacturing site to become Bristol-Myers Squibb's center for excellence for our therapeutic compounds.
Princeton Pike, New Jersey
The newly constructed 650,000-square foot facility opened November 2016 and houses employees from the Commercial teams, their commercialization and late-stage development partners from Research & Development and Global Manufacturing & Supply and their enabling function support teams.
Lawrenceville, New Jersey
The 276-acre campus serves as Bristol-Myers Squibb's Research and Development headquarters. Here scientists discover and develop medicines in the areas of cancer, immunology, and cardiovascular diseases. The campus has 13 connected buildings totaling 1.5 million square feet.
Bristol-Myers Squibb's European and French headquarters located 45 minutes from downtown Paris. The building, opened in August 2002, was designed by internationally recognized architect Jean-Paul Viguier.
Redwood City, California
The 256,000 square-foot Bay Area research facility houses biologics drug discovery activities focused on antibody therapeutics. The Redwood City location provides proximity to major biomedical research centers such as University of California Berkeley, University of California San Francisco and Stanford University.
A renewed Seattle landmark steam plant now provides a high-tech home for ZymoGenetics, a biotechnology firm acquired by Bristol-Myers Squibb in 2010. ZymoGenetics discovers and develops therapeutic proteins for the prevention and treatment of serious diseases.
The Waltham facility is a discovery site which supports the identification and optimization of drug candidates across modalities in Discovery Research and Development.